Prinomastat hydrochloride, >=95% (HPLC)

Code: pz0198-25mg D2-231

Not available outside of the UK & Ireland.

Application

Prinomastat hydrochloride has been used as an antagonist for metalloproteinases (MMPs) in Crotalus atrox venom samples and mouse embryo cultures. It may ...


read more

Your Price
£464.00 25MG

Not available outside of the UK & Ireland.

Application

Prinomastat hydrochloride has been used as an antagonist for metalloproteinases (MMPs) in Crotalus atrox venom samples and mouse embryo cultures. It may be used as a MMP-2 inhibitor in HepG2 cells.

Biochem/physiol Actions

Prinomastat is a matrix metalloprotease (MMP) inhibitor with selectivity for MMPs 2, 3, 9, 13, and 14. Inhibition of these MMPs has been postulated to block tumor invasion and metastasis. It is extremely potent at MMP-3 and MMP-2 with IC50s, 30 pM & 50 pM, respectively.

General description

Prinomastat comprises hydroxamic acid group and chelates with zinc ion.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Cytoskeleton & Extracellular Matrix research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

assay≥95% (HPLC)
colorwhite to beige
formpowder
InChI keyUQGWXXLNXBRNBU-NTISSMGPSA-N
InChI1S/C18H21N3O5S2.ClH/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14;/h3-10,16,23H,11-12H2,1-2H3,(H,20,22);1H/t16-;/m0./s1
manufacturer/tradenamePfizer®
originatorPfizer
Quality Level100
SMILES stringCl.CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c2ccc(Oc3ccncc3)cc2
solubilityH2O: 15 mg/mL (clear solution)
storage temp.room temp
Code
Description
Unit Size
List Price
Qty
PZ0198-5MG
Unit:5MG
List Price: £117.00
Source:List Price
ADD
This product has met the following criteria: